Source: China News Network
Beijing, December 15 (Reporter Zhang Ni) At present, the national drug collection has been carried out for more than 3 years. On the one hand, the price of the selected drugs has dropped significantly, bringing real benefits to patients. On the other hand, the outside world is also concerned about the situation of those drugs that have not been selected, especially the original research drugs. Have their prices and purchase volumes changed significantly? In a set of data released by the China Medical Insurance Research Association, the answer may be found.
Data chart: Zhejiang Anji automatic drug dispensing machine "on the job" Yu Danfei photo
The "substitution effect" of the selected generic drugs is obvious
On the 15th, China Medical Insurance magazine held a press conference in Beijing on the "change in the use of the original research drugs that have not been selected in the collection - the dosage is 'two minus one increase' and the price is 'three prices are falling together'".
According to the meeting, the China Medical Insurance Research Association selected 9 kinds of drugs such as atorvastatin oral regular-release dosage forms and amlodipine oral regular-release dosage forms, and compared the price and procurement volume of the year before and after the implementation of the collection results according to the incomplete statistics of the national situation.
The data shows that from the perspective of drug procurement, the purchase volume of unselected original research drugs has decreased significantly, and the "substitution effect" of selected generic drugs on the original drugs that have not been selected is obvious.
One year after the implementation of the collection results, the total annual procurement volume of the original research drugs that were not selected decreased by an average of 46% compared with the year before the implementation of the collection results. Among them, simvastatin oral regular-release agents decreased the most, reaching 74.4%; followed by aluminum magnesium carbonate chewable tablets, with a decrease of 60.3%; again, valsartan oral regular-release dosage forms, a decrease of 55%; and imatinib oral regular-release dosage forms with the least reduction also reached 13.4%.
The total annual procurement volume of unselected generic drugs fell by 80.8%, 9 drugs fell by more than 70%, and 6 drugs fell by more than 80%. Among them, atorvastatin oral regular-release dosage form decreased the most, reaching 94.9%.
In contrast, the total annual procurement volume of selected generic drugs increased by 265.2%, of which omeprazole oral regular-release agents increased the most, reaching 522.6%,, followed by amlodipine oral regular-release agents with an increase of 506.5%,; and the smallest increase in imatinib oral regular-release agents also reached 54.5%.
Data map: People lining up in the outpatient building of a hospital to register. China News Service reporter Yin Liqin photographed
The price is reduced if you don't win! The burden of medication on the masses has been reduced
It is worth mentioning that the study also shows that under the same generic name, the original research drugs, the selected generic drugs and the unselected generic drugs have "dropped in three prices", and the burden of medication for the masses has been significantly reduced.
Among them, the price of selected generic drugs has fallen most significantly. The effect of "volume-for-price" was obvious, with an average price reduction of 82.4% in the prices of the 9 selected generic drugs, of which entecavir oral regular-release dosage forms decreased the most, reaching 90.1%, followed by atorvastatin oral regular-release dosage forms, with a decrease of 83.1%. The oral regular-release dosage form of imatinib, which had the lowest reduction, also reached 21.8%.
In addition, according to the decline in the price of the selected generic drugs, the medical insurance departments in various places have linked up to lower the price of the corresponding non-selected original research drugs, or anchored the lowest price in the country, or anchored the Purchase Price in Shanghai, guiding the price of the original research drugs of the non-selected original research drugs to decline.
The average reduction of the unselected original research drugs of the 9 drugs reached 12.9%. Among them, valsartan oral regular-release dosage form decreased the most, reaching 20.8%; followed by atorvastatin oral regular-release dosage form, with a decrease of 20.7%; and again, rosuvastatin oral regular-release dosage form, with a decrease of 19.0%. The least reduced amount of chewable aluminum magnesium carbonate tablets also reached 6.5%.
The price of unselected generic drugs also fell with the trend. The average reduction rate of the 9 unselected generic drugs was 17.4%. Among them, the oral regular-release dosage form of entecavir had the largest decline of 34.3%,, followed by simvastatin oral regular-release dosage form with a decrease of 19.9%,; and the second imatinib oral regular-release dosage form, with a decrease of 18.3%. The least reduced amount of chewable aluminum magnesium carbonate also reached 3.4%.
It was introduced at the meeting that the price reduction effect will continue to be released in 2021. Compared with the year after the implementation of the collection results, the average price of drugs in 2021 decreased by 25.7%, of which the average decline of selected drugs was 29.1%.
In addition, the selected generic drugs continue to replace the original drugs that have not been selected and the generic drugs that have not been selected, and the effect of "generic drug substitution" has continued to strengthen.
Compared with the year after the implementation of the collection results, the market share of selected generic drugs in 2021 further increased to 84.4%, an increase of 5.2 percentage points; the market share of original drugs further decreased to 11.7%, down 3.9 percentage points; the market share of selected generic drugs of each drug was more than 80%, and the market share of 3 drugs has reached more than 90%. (End)